The gut is one of the body’s most complex and consequential organ systems. The approximately four hundred square metres of intestinal surface area in an adult human hosts trillions of microbial organisms collectively known as the gut microbiome, manages the absorption of virtually all nutrients entering the body, coordinates the largest component of the immune system outside the bloodstream, and maintains a continuous chemical dialogue with the brain through the enteric nervous system. Disrupting any component of this system has consequences that radiate across health in ways that are still being actively mapped by research.
Nicotine and the compounds present in vaping aerosol interact with the gut through multiple pathways: systemic absorption from the lungs, direct ingestion of small quantities of swallowed vapour, and the neurological effects of nicotine on the enteric nervous system. The research on these interactions is less developed than the literature on lung and cardiovascular effects, partly because the gut was historically considered too remote from the lungs to be meaningfully affected by inhaled substances. That assumption has been revised substantially over the past decade as the mechanisms of gut-lung crosstalk have been better understood.
Nicotine and the Enteric Nervous System
The enteric nervous system — sometimes described as the body’s second brain — is the extensive network of neurons embedded in the wall of the gastrointestinal tract that coordinates the muscular contractions of digestion, regulates fluid secretion, and modulates local immune responses in the gut wall. It contains roughly five hundred million neurons, comparable to the spinal cord, and operates largely independently of the central nervous system, though the two communicate continuously through the vagus nerve.
Nicotinic acetylcholine receptors are expressed throughout the enteric nervous system, and nicotine acts directly on these receptors to alter gut motility — the rhythmic muscular contractions that move food through the digestive tract. The effects are dose-dependent and complex: at lower concentrations, nicotine tends to accelerate gastric emptying and increase colonic transit speed, which is why many smokers report a consistent post-cigarette bowel habit. At higher concentrations, nicotine can suppress motility in some regions while accelerating it in others, producing variable effects including cramping, altered transit time, and changes in stool consistency.
This motility effect is one of the better-documented gastrointestinal consequences of nicotine use, and it applies to vapers as well as smokers. Vapers who switch from cigarettes and experience changes in their bowel habits in the first weeks are often observing this nicotine-mediated effect, and the disruption typically stabilises as the body adapts to the new delivery pattern. However, for individuals with pre-existing conditions affecting gut motility — including irritable bowel syndrome, Crohn’s disease, and gastroparesis — the nicotine effects on the enteric nervous system can be clinically significant and warrant discussion with a gastroenterologist.
Nicotine’s Effects on Gut Acid and the Oesophagus
The relationship between nicotine and gastro-oesophageal reflux disease (GORD) has been documented in smokers for decades, and the underlying mechanism is directly relevant to vapers. Nicotine relaxes the lower oesophageal sphincter — the valve between the oesophagus and stomach that normally prevents the backward flow of stomach acid. When this sphincter is relaxed by nicotine, acid reflux becomes more likely, producing the characteristic burning sensation of heartburn and, over time, contributing to oesophageal inflammation.
Research comparing reflux rates in smokers, vapers, and non-users has found that both smoking and vaping are associated with higher rates of symptomatic reflux than non-use of nicotine, though the comparison between smoking and vaping is less clear. The combustion-specific compounds in cigarette smoke have additional effects on oesophageal tissue that vaping does not replicate, but the sphincter-relaxing effect of nicotine itself is present in both.
Vapers who experience increased heartburn symptoms or reflux after starting vaping or after changing their vaping habits should consider the nicotine component as a likely contributor. Reducing nicotine concentration in liquids used in the evening, avoiding vaping for an hour before lying down, and maintaining a head-elevated sleeping position are practical mitigations that work for nicotine-related reflux regardless of the delivery mechanism.
The Gut Microbiome and Nicotine Exposure
The gut microbiome — the community of bacteria, fungi, viruses, and archaea that inhabit the gastrointestinal tract — is now understood to be a critical mediator of health across virtually every organ system. The composition of this community influences immune function, metabolic health, mental health through the gut-brain axis, and even cardiovascular risk. Disruptions to microbiome composition, known as dysbiosis, are associated with a wide range of conditions from inflammatory bowel disease to obesity to depression.
Research on the effects of nicotine on gut microbiome composition is relatively recent and still evolving, but the initial findings are consistent with the direction suggested by what is known about nicotine’s other biological effects. Animal studies have demonstrated that nicotine exposure alters the relative abundance of several bacterial genera in the gut, reducing populations of bacteria associated with butyrate production — a short-chain fatty acid critical for the health of the intestinal lining — and increasing populations of bacteria associated with inflammatory states.
Human studies comparing the microbiome of smokers, ex-smokers, and non-smokers have found significant differences in microbial diversity and composition, with smokers showing reduced alpha diversity — the variety of species within the gut — compared to non-smokers. Ex-smokers who quit show partial restoration of microbiome diversity over months to years, suggesting that at least some of the nicotine-associated changes are reversible. Data specifically on vapers is limited, but the nicotine-specific mechanisms identified in animal studies and the partial relevance of smoking data suggest that regular vaping is likely to have some effect on microbiome composition through the systemic nicotine exposure it creates.
Swallowed Aerosol and Direct Gut Exposure
A proportion of the aerosol inhaled during vaping is not retained in the respiratory tract — some is swallowed, delivering the flavour compounds, propylene glycol, vegetable glycerin, and any residual nicotine directly to the gastrointestinal tract. The quantity involved per vaping session is small, but for regular vapers who vape multiple times throughout the day over extended periods, the cumulative direct gut exposure to these compounds is not trivial.
Propylene glycol and vegetable glycerin are both generally recognised as safe food additives and are consumed in much larger quantities through food than through vaping in most people’s diets. The inhaled quantities that are subsequently swallowed are unlikely to be problematic at typical usage levels. Flavour concentrate compounds are a more variable consideration, given the diversity of ingredients used across the e-liquid market and the limited data on gastrointestinal exposure to many of these compounds specifically. This is one of the arguments for choosing e-liquids from manufacturers who invest in safety testing and ingredient transparency.
Inflammatory Bowel Conditions and Vaping
The relationship between nicotine and inflammatory bowel disease is one of the more paradoxical areas in gastrointestinal research. Epidemiological data consistently shows that Crohn’s disease is more common in current and former smokers, while ulcerative colitis is less common in current smokers and tends to relapse or worsen upon smoking cessation. This counter-intuitive finding has driven decades of research into the anti-inflammatory effects of nicotine in the colonic environment specifically.
Several clinical trials have examined nicotine patches as a treatment for ulcerative colitis, with mixed but generally modestly positive results in reducing inflammatory activity during active flares. The mechanism appears to involve nicotine’s effects on colonic mucus production, local immune modulation, and colonic motility. These findings have not translated into clinical recommendations for nicotine use in ulcerative colitis management, but they inform the understanding of why the condition behaves differently in nicotine users.
For vapers with inflammatory bowel disease, the implications are complex and individual. Neither smoking nor vaping should be recommended as a therapeutic strategy for IBD. However, vapers with IBD who are considering stopping nicotine use should be aware that cessation may be associated with changes in their condition and should discuss the timing and approach to nicotine reduction with their gastroenterologist rather than managing it independently.
Practical Considerations for Vapers
For most vapers without pre-existing gastrointestinal conditions, the gut effects of vaping are likely to be modest and manageable. The most practically relevant considerations are: avoiding vaping immediately before or after meals if you notice digestive discomfort; maintaining adequate hydration to compensate for the gut-drying effects of propylene glycol and vegetable glycerin; and being attentive to new or worsening reflux symptoms that might be nicotine-related.
For vapers with existing gastrointestinal conditions, a conversation with their gastroenterologist or GP about their vaping habits is worthwhile. The interactions between nicotine and conditions like GORD, IBS, Crohn’s disease, and ulcerative colitis are complex enough that individual clinical guidance, rather than general population-level advice, is the appropriate basis for decisions.
The gut health research on vaping is still in early development relative to the cardiovascular and respiratory literature. Vapers who want to stay informed about this topic should look for systematic reviews from gastroenterology research groups rather than relying on individual study findings, which can be variable and may not translate directly from animal models to human experience.